New arylsparteine derivatives as positive inotropic drugs

References

• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–442.
   PubMed Web of Science ®Google Scholar
• Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993;22:1223–7.
   PubMed Web of Science ®Google Scholar
• Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol 2014;63:2069–78.
   PubMed Web of Science ®Google Scholar
• Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci 2015;16:29060–8.
   PubMed Web of Science ®Google Scholar
• Endoh M, Hori M. Basic pharmacology and clinical application of new positive inotropic agents. Drugs Today 1993;29:29–54.
   Google Scholar
• Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 2015;89:1401–38.
   PubMed Web of Science ®Google Scholar
• Matsumori A. The role of NF-kappaB in the pathogenesis of heart failure and endotoxemia. Drugs Future 2004;29:733–9.
   Web of Science ®Google Scholar
• Shin DD, Brandimarte F, De Luca L, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007;99:4A–23A.
   PubMed Web of Science ®Google Scholar
• Suffredini S, Mugelli A, Cerbai E. I(f) channels as a therapeutic target in heart disease. Future Cardiol 2007;3:657–66.
   PubMedGoogle Scholar
• Tamargo J, Duarte J, Caballero R, Delpón E. New therapeutic targets for the development of positive inotropic agents. Discov Med 2011;12:381–92.
   PubMed Web of Science ®Google Scholar
• (a) Forster N, Hoefke W. A comparison of the effects of sparteine, quinidine and nicotine on isolated myocardium of rats and cats. Naunyn–Schmiedeberg’s Arch. Expt Pathol Pharmakol 1960;239:383–92.
   PubMedGoogle Scholar
  (b) von Philipsborn G, Wilhelm E, Homburger H. Effect of sparteine in the isolated atrial myocardium of guinea-pigs. Naunyn-Schmiedeberg’s Arch Pharmacol 1973;277:281–90.
   Google Scholar
  (c) Raschack M. Actions of sparteine and sparteine derivatives on the heart and circulation. Arzneim Forsch 1974;24:753–9.
   PubMed Web of Science ®Google Scholar
  (d) Engelmann K, Raake W, Petter A. The importance of hydrophobic groups for the antiarrhythmic results of alkylated sparteine. Arzneim Forsch 1974;24:759–61.
   Google Scholar
• Schmidt HD, Padeken D, Beck L. Cardiovascular effect of sparteine in anaesthetized dogs with and without blockade of cardiac autonomic nerves. Arzneim Forsch 1986;36:1481–4.
   PubMed Web of Science ®Google Scholar
• Kimura M, Kimura I, Chui L-H, Okuda S. Positive inotropic action and conformation difference of lupin alkaloids in isolated cardiac muscle of guinea pig and bullfrog. Phytother Res 1989;3:101–5.
   Web of Science ®Google Scholar
• Zetler G, Strubelt O. Antifibrillatory, cardiovascular and toxic effects of sparteine, butylsparteine and pentylsparteine. Arzneimittelforschung 1980;30:1497–502.
   PubMed Web of Science ®Google Scholar
• (a) Schoen U, Kehrbach W, Hachmeister B, et al. Ger. Offen. DE3522475-A1-19870102. Chem Abstr 1987;106:156761s.
   Google Scholar
  (b) Schoen U, Kehrbach W, Hachmeister B, et al. Ger. Offen. DE3643402-A1-19880630. Chem Abstr 1988;110:63753h.
   Google Scholar
• (a) Winterfeld K, Hoffmann E. Über das Verhalten des Lupanins bei der Grignardierung (Zugleich XII. Mitteilung über die Alkaloide der Lupinen). Arch Pharm 1937;275:5–27.
   Google Scholar
  (b) Winterfeld K, Hoffmann E. Zur Kenntnis des Anisoyl-Sparteins (Zugleich XIV. Mitteilung über die Alkaloide der Lupinen). Arch Pharm 1937;275:526–32.
   Google Scholar
• Jack W. Untersuchung einiger Sparteinabkömmlinge auf die flimmerwidrige Wirkung am Froschherzen. Arch Exptl Pathol Pharmakol 1942;200:528–35.
   Google Scholar
• (a) Sparatore F, Boido V, Preziosi P, et al. Synthesis and pharmacodynamic properties of various lupinane derivatives. Farmaco, Ed. Sci 1969;24:587–621.
   PubMedGoogle Scholar
  (b) Boido V, Boido A, Boido Canu C, Sparatore F. Quinolozidinylalkylamines with antihypertensive activity. Farmaco, Ed. Sci 1979;34:673–87.
   PubMedGoogle Scholar
• (a) Canu Boido C, Sparatore F. Synthesis and preliminary pharmacological evaluation of some cytisine derivatives. Farmaco 1999;54:438–51.
   PubMedGoogle Scholar
  (b) Canu Boido C, Tasso B, Boido V, Sparatore F. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. Farmaco 2003;58:265–77.
   PubMedGoogle Scholar
• (a) Sparatore A, Sparatore F. Preparation and pharmacological activities of 10-homolupinanoyl-2-R-phenothiazines. Farmaco 1994;49:5–17.
   PubMedGoogle Scholar
  (b) Sparatore A, Sparatore F. Preparation and pharmacological activities of homolupinanoyl anilides. Farmaco 1995;50:153–66.
   PubMedGoogle Scholar
• Vazzana I, Budriesi R, Terranova E, et al. Novel quinolizidinyl derivatives as antiarrhythmic agents. J Med Chem 2007;50:334–43.
   PubMed Web of Science ®Google Scholar
• Tasso B, Budriesi R, Vazzana I, et al. Novel quinolizidinyl derivatives as antiarrhythmic agents: 2. Further investigation. J Med Chem 2010;53:4668–77.
   PubMed Web of Science ®Google Scholar
• Boczón W. Further studies on the stereochemistry of sparteine, its isomers and derivatives. XV. Synthesis, structure and spectroscopic properties of 2-methyl-2-dehydrosparteine and 2-(p-tolyl)-2-dehydrosparteine (free bases) and their diprotonated salts. Bull Pol Acad Sci Chem 1988;36:21–36.
   Google Scholar
• Boczón W, Koziol B. Further studies on the stereochemistry of sparteine, its isomers and derivatives. XXIV. 2-(p-Tolyl)sparteine and its monoperchlorate salt. J Mol Struct 1997;403:171–81.
   Web of Science ®Google Scholar
• MOE: Chemical Computing Group Inc. Montreal. H3A 2R7 Canada. http://www.chemcomp.com.
   Google Scholar
• (a) Fossa P, Cichero E. In silico evaluation of human small heat shock protein HSP27: homology modeling, mutation analyses and docking studies. Bioorg Med Chem 2015;23:3215–20.
   PubMed Web of Science ®Google Scholar
  (b) Franchini S, Manasieva LI, Sorbi C, et al. Synthesis, biological evaluation and molecular modeling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT1A receptor agonists. Eur J Med Chem 2016;125:435–52.
   PubMed Web of Science ®Google Scholar
  (c) Deiana V, Gómez-Cañas M, Pazos MR, et al. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. Eur J Med Chem 2016;112:66–80.
   PubMed Web of Science ®Google Scholar
• Ligon EWm. Jr., Action of lupine alkaloids on the motility of the isolated rabbit uterus. J Pharmacol 1941;73:151–8.
   Google Scholar
• (a) Sparatore A, Novelli F, Sparatore F. Quinolizidine derivatives as ligands for sigma receptors. Med Chem Res 2002;11:1–11.
   Web of Science ®Google Scholar
  (b) Sparatore A, Novelli F, Sparatore F. 1-(Arylalkyl)quinolizidine derivatives and thio-isosteric analogs as ligands for sigma receptors. Helv Chim Acta 2004;87:580–91.
   Web of Science ®Google Scholar
• (a) De Costa BR, Radesca L, Di Paolo L, Bowen WD. Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor. J Med Chem 1992;35:38–47.
   Google Scholar
  (b) Glennon RA. Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the “deconstruction-reconstruction-elaboration” approach. Mini Rev Med Chem 2005;5:927–40.
   PubMed Web of Science ®Google Scholar
  (c) Matsumoto RR, Bowen WD, Su TP. Sigma receptors. Chemistry, cell biology and clinical implications. New York: Springer; 2007. ISBN 978-0-387-36514-5.
   Google Scholar
• Monassier L, Bousquet P. Sigma receptors: from discovery to highlights of their implications in the cardiovascular system. Fundam Clin Pharmacol 2002;16:1–8.
   PubMed Web of Science ®Google Scholar
• Zhang H, Cuevas J. Sigma receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J Pharmacol Exp Ther 2005;313:1387–96.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MS, Fukunaga K. Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin Ther Targets 2011;15:145–55.
   PubMed Web of Science ®Google Scholar
• Novakova M. Effects of sigma receptor ligand BD737 in rat isolated hearts. Scr Med (Brno) 2007;80:255–62.
   Google Scholar
• Novakova M, Bruderova V, Sulova Z, et al. Modulation of expression of the sigma receptors in the heart of rat and mouse in normal and pathological conditions. Gen Physiol Biophys 2007;26:110–17.
   PubMed Web of Science ®Google Scholar
• (a) Laurini E, Marson D, Dal Col V, et al. Another brick in the wall. Validation of the σ1 receptor 3D model by computer-assisted design, synthesis, and activity of new σ1 ligands. Mol Pharm 2012;9:3107–26.
   PubMed Web of Science ®Google Scholar
  (b) Franchini S, Battisti UM, Prandi A, et al. Scouting new sigma receptor ligands: synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives. Eur J Med Chem 2016;112:1–19.
   PubMed Web of Science ®Google Scholar
• Meyer C, Schepmann D, Yanagisawa S, et al. Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor. J Med Chem 2012;55:8047–65.
   PubMed Web of Science ®Google Scholar
• Brune S, Schepmann D, Klempnauer KH, et al. The sigma enigma: in vitro/in silico site-directed mutagenesis studies unveil σ1 receptor ligand binding. Biochemistry 2014;53:2993–3003.
   PubMed Web of Science ®Google Scholar
• Schmidt HR, Zheng S, Gurpinar E, et al. Crystal structure of the human σ1 receptor. Nature 2016;532:527–30.
   PubMed Web of Science ®Google Scholar